Drug intelligence / Profile preview

LAU_OP-12

Development stage: Unknown
Lead developer: Vectans Pharma
Modality: Small Molecules
Administration: Buccal

Overview

LAU_OP-12 is a clinical-stage drug candidate being developed by Vectans Pharma for the treatment of acute oral pain. The product utilizes the proprietary Lauriad muco-adhesive buccal tablet technology, which is designed to adhere to the oral mucosa (typically the gum) to provide sustained and controlled release of the active ingredient directly at the site of action or for systemic absorption. As of late 2021, the program was in Phase 1 development. The specific active pharmaceutical ingredient (API) contained within the LAU_OP-12 formulation has not been publicly disclosed by the developer.

Beyond the preview

Go deeper on LAU_OP-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAU_OP-12.